For the quarter ending 2025-09-30, SRE had $2,842M increase in cash & cash equivalents over the period. -$1,451M in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Net income | 150 | 519 | 919 | 989 |
| Depreciation and amortization | 662 | 653 | 640 | 626 |
| Deferred income taxes and investment tax credits | 430 | 176 | -48 | 203 |
| Equity earnings | 472 | 393 | 325 | 374 |
| Share-based compensation expense | 14 | 13 | -2 | 23 |
| Fixed-price contracts and other derivatives | -51 | 52 | -134 | 208 |
| Bad debt expense | 72 | 31 | 6 | 60 |
| Other | -39 | 33 | 3 | -13 |
| Accounts receivable | - | - | - | -118 |
| Due to/from unconsolidated affiliates, net | - | - | - | -30 |
| Income taxes receivable/payable, net | - | - | - | -49 |
| Inventories | - | - | - | 74 |
| Other current assets | - | - | - | 30 |
| Accounts payable | - | - | - | -131 |
| Regulatory balancing accounts, net | - | - | - | 456 |
| Reserve for aliso canyon costs | - | - | - | -12 |
| Other current liabilities | - | - | - | 142 |
| Insurance receivable for aliso canyon costs | - | - | - | 0 |
| Net change in working capital components | 247 | 463 | 90 | - |
| Distributions from investments | 312 | 225 | 291 | 439 |
| Changes in other noncurrent assets and liabilities, net | -99 | -108 | 95 | -111 |
| Net cash provided by operating activities | 1,110 | 784 | 1,482 | 1,365 |
| Expenditures for property, plant and equipment | 2,561 | 2,304 | 2,336 | 2,450 |
| Expenditures for investments | 520 | 486 | 486 | 400 |
| Return on investments | - | - | - | 9 |
| Purchases of nuclear decommissioning and other trust assets | 215 | 239 | 292 | 231 |
| Proceeds from sales of nuclear decommissioning and other trust assets | 251 | 251 | 329 | 238 |
| Repayments of advances to unconsolidated affiliates | - | - | - | 0 |
| Other | -3 | 0 | 0 | -12 |
| Net cash used in investing activities | -3,042 | -2,778 | -2,785 | -2,822 |
| Common dividends paid | 408 | 407 | 380 | 378 |
| Preferred dividends paid | 0 | 22 | - | 22 |
| Issuances of common stock | 7 | 9 | 10 | 1,193 |
| Repurchases of common stock | 0 | 1 | 57 | 2 |
| Issuances of debt (maturities greater than 90 days) | 3,434 | 2,517 | 2,941 | 2,237 |
| Payments on debt (maturities greater than 90 days) and finance leases | 731 | 2,417 | 994 | 1,123 |
| Decrease in short-term debt, net | -852 | 752 | -70 | 372 |
| Advances from unconsolidated affiliates | 52 | 0 | 44 | 0 |
| Contributions from contingently redeemable noncontrolling interest, net of transaction costs | 3,212 | - | - | - |
| Proceeds from investor equity subscription | 106 | - | - | - |
| Contributions from noncontrolling interests | 54 | 49 | 34 | 114 |
| Proceeds from sales of noncontrolling interests, net | - | - | - | 0 |
| Termination of interest rate and settlement of cross-currency swaps | - | - | - | -46 |
| Distributions to noncontrolling interests | 40 | 53 | 38 | 62 |
| Other | -64 | -12 | -14 | -17 |
| Net cash provided by financing activities | 4,770 | 415 | 1,476 | 2,358 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 3 | 1 | 0 | -2 |
| Less increase in cash held for sale | - | 1 | - | - |
| Increase in cash, cash equivalents and restricted cash | 2,842 | -1,579 | 173 | 899 |
| Cash and cash equivalents at beginning of period | 183 | 1,762 | 1,589 | 690 |
| Cash and cash equivalents at end of period | 3,025 | 183 | 1,762 | 1,589 |
SEMPRA (SRE)
SEMPRA (SRE)